(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Fibrobiologics's earnings in 2026 is -$18,501,000.On average, 6 Wall Street analysts forecast FBLG's earnings for 2026 to be -$17,978,753, with the lowest FBLG earnings forecast at -$22,692,130, and the highest FBLG earnings forecast at -$14,047,509. On average, 6 Wall Street analysts forecast FBLG's earnings for 2027 to be -$13,646,152, with the lowest FBLG earnings forecast at -$30,760,443, and the highest FBLG earnings forecast at $12,966,931.
In 2028, FBLG is forecast to generate -$33,852,953 in earnings, with the lowest earnings forecast at -$42,862,912 and the highest earnings forecast at -$23,772,708.